Cerulean Pharma Inc, a clinical-stage company developing nanoparticle-drug conjugates (NDCs), announced top-line results from the company's phase 2, randomized, multi-center clinical trial of its lead candidate, CRLX101, in combination with Avastin (bevacizumab) in the treatment of patients with advanced renal cell carcinoma (RCC).
Supernus Pharmaceuticals, Inc. announced that the Food and Drug Administration (FDA) has granted tentative approval to the Company's Supplemental New Drug Application (sNDA) requesting a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.